How Purdue Pharma and the Sacklers Built the Opioid Crisis

When Richard Sackler, member of the billionaire Sackler family and executive at Purdue Pharma, received an internal memo in 1996 titled "Concentration of Opioid Use in a Small Number of Patients," it contained a warning: the company's new blockbuster painkiller OxyContin was creating a small population of heavily dependent users. Instead of heeding the warning, Purdue accelerated its marketing campaign. Within five years, opioid-related deaths would spike across America. Within two decades, over 600,000 Americans would be dead from the opioid crisis Purdue helped engineer.

This is not speculation. Court records, FDA documents obtained through FOIA requests, DEA files, and deposed testimony from company executives form a paper trail documenting corporate negligence that ranks among the most destructive pharmaceutical conspiracies in American history.

Quick Answer

Purdue Pharma deliberately misrepresented OxyContin's addiction risk to doctors and patients while suppressing internal research showing the drug's dangers. Court settlements, FDA records, and Department of Justice filings prove executives knowingly violated federal drug laws. The Sackler family's fortune, estimated at $11 billion, was built directly on these illegal practices and the resulting public health catastrophe.

What Happened

In December 1995, the FDA approved OxyContin (oxycodone extended-release) for moderate to severe pain. Purdue Pharma was not a large pharmaceutical company; it was a family business owned and operated by the Sacklers, descendants of Arthur Sackler, who had pioneered aggressive pharmaceutical marketing decades earlier. From day one, OxyContin was marketed with claims that would later be proven false in federal court.

Purdue distributed sales literature claiming OxyContin carried "less addiction potential" than other opioids and posed "minimal" addiction risk when used as directed. Internal emails and deposition testimony later revealed this was corporate deception. The company had not conducted adequate addiction studies. What they had were internal market analyses showing OxyContin could generate $1 billion in annual revenue if they could expand the market beyond cancer pain patients (the original approved use) to chronic pain sufferers.

Between 1996 and 2002, Purdue more than doubled its sales force and deployed an aggressive direct-to-consumer and physician marketing strategy. Representatives distributed patient education materials, funded speaker programs, sponsored medical conferences, and paid doctors to speak about pain management. The core message: opioids are safe when properly prescribed.

This marketing strategy was coordinated from the top. Court documents from the 2007 United States v. Purdue Pharma et al. case (filed in the U.S. District Court for the Western District of Virginia, Civil Action No. 2:07cv00469) reveal that company executives, including Richard Sackler, received regular sales updates. An email from Richard Sackler dated January 1, 1997, states: "The introduction of OxyContin has been a great success... We have already begun the process of building up a dedicated sales force to market OxyContin to physicians." Another internal memo from 1997 discusses "maximizing market penetration" regardless of addiction concerns.

The FDA, meanwhile, received warnings from the DEA. Internal DEA correspondence from 1999-2000, available through FOIA requests to the Drug Enforcement Administration, flagged suspicious orders of oxycodone precursor chemicals and diversion to the black market. Purdue's response was to request the FDA remove addiction warnings from OxyContin's label. The FDA, understaffed and under political pressure, complied in 2003, removing the prominent black box warning about addiction from marketing materials.

By 2000, prescription opioid deaths began climbing. Poison control centers received 6,000 calls related to oxycodone in 1999; by 2002, that number exceeded 16,000. State medical boards documented cases of doctors running "pill mills," many of whom had received payment from Purdue for speaking engagements or attending Purdue-sponsored conferences.

Purdue's internal awareness of the crisis is documented in emails and memos later released through litigation discovery. A 1998 internal presentation obtained by the Massachusetts Attorney General's office warned that "patients [are] taking the drug for non-medical purposes" and that OxyContin had become "the drug of choice" in certain communities. Company executives did not halt marketing; they refined it.

The company also strategically limited access to naloxone, an opioid antagonist that reverses overdose. While naloxone became publicly available, Purdue did not include it with OxyContin prescriptions or fund widespread naloxone distribution programs, despite knowing overdose risk was significantly higher than claimed in marketing materials.

The Evidence

The primary documentary evidence comes from four categories of official records:

1. Federal Court Records and Settlements

In 2007, Purdue Pharma pleaded guilty to criminal charges of misleading regulators, doctors, and patients about OxyContin's addiction risk. The company and three executives (Michael Friedman, Howard Udell, and Paul Scranton) paid $635 million in fines. The plea agreement (Case No. 2:07cv00469, U.S. District Court, Western District of Virginia) explicitly states that Purdue knowingly misrepresented "the addictive properties, risks of abuse, and risks of overdose" of OxyContin.

In 2020, after years of consolidated litigation, Purdue agreed to a broader settlement framework worth up to $8 billion, with direct admissions that the company engaged in a "scheme to defraud" the United States and fraudulently marketed OxyContin. The settlement Complaint and Settlement Agreement (In re National Prescription Opiate Litigation, MDL No. 2804, filed in the U.S. District Court for the Northern District of Ohio) contains detailed factual admissions backed by discovery documents.

2. FDA and DEA Documents (FOIA Releases)

Through Freedom of Information Act requests, researchers have obtained DEA Internal Communications memos from 1999-2003 documenting suspicious wholesale oxycodone orders. The DEA's Suspicious Order Reporting System flagged Purdue for supplying distributors that shipped disproportionate quantities to states later identified as opioid crisis hotspots (West Virginia, Kentucky, Ohio).

FDA correspondence released through FOIA shows the agency received internal Purdue studies in the 1990s that contradicted marketing claims. A 1996 Purdue-funded study titled "Addiction Is Rare in Patients Treated with Narcotics," which had an extremely small sample size and excluded patients with substance abuse history, became the basis for claims of "minimal addiction risk." FDA scientists flagged methodological problems in internal memos, but the marketing claims persisted.

3. Deposition and Email Evidence from Litigation Discovery

Depositions of Purdue executives and board members, released through court orders in consolidated litigation, contain direct admissions. Richard Sackler's deposition in the Massachusetts case (2015) confirmed he received reports of OxyContin abuse as early as 1997 but continued overseeing marketing campaigns. Email chains between executives use language like "we need to hammer on the pain message" and discuss shifting marketing focus to pain when addiction concerns surfaced publicly.

A 2001 email from Curtis Wright, a Purdue consultant and former FDA official, to company executives states: "We need to head off the use of OxyContin as a blunt nail in the coffin... We have to make sure the coffin stays closed." This was sent after news reports of OxyContin abuse began appearing.

4. State Attorney General Filings and Investigative Reports

The Massachusetts Attorney General's office conducted a detailed investigation (2015-2020) resulting in a civil lawsuit with attached exhibits including internal Purdue marketing budgets, sales representative training materials emphasizing aggressive marketing despite known addiction risks, and financial records showing payments to pain advocacy groups that promoted opioid use.

The New York Attorney General's office released investigative findings (published 2018) documenting Purdue's payments to doctors totaling millions annually and strategic sponsorships of patient advocacy organizations, many of which did not disclose Purdue's financial support when promoting broader opioid prescribing.

Why It Matters

The Purdue Pharma case demonstrates how a single company, guided by a wealthy family with financial incentives divorced from public health, can engineer a public health catastrophe with the complicity of regulatory agencies and the silence of an industry that benefited from expanded opioid markets.

Over 650,000 Americans have died from opioid overdoses since 1996. The CDC estimates 2.7 million Americans are living with opioid use disorders. The economic cost to the U.S. healthcare system and criminal justice system exceeds $1 trillion annually. Families across rural and urban America were devastated while Purdue's executives and the Sackler family accumulated one of the largest private fortunes in modern history.

The case also exposes regulatory failure. The FDA, despite receiving internal warnings from its own scientists, approved marketing claims it knew were unsupported. The DEA, which has authority to limit oxycodone manufacturing, did not meaningfully restrict Purdue's supply chain even after flagging suspicious orders. The Department of Justice, in settlements, chose financial penalties over criminal prosecution of most executives involved, a pattern that has enabled corporate impunity in pharmaceutical misconduct cases.

Purdue's marketing strategy, refined through litigation and documented in court records, became a template for how pharmaceutical companies could expand opioid markets by targeting specific medical specialties, paying doctors to promote use, and strategically framing addiction as a management problem rather than an inherent drug property. This model has been replicated in marketing for other controlled substances.

The Sackler family's role is particularly significant because it demonstrates that wealth accumulated through fraud is rarely fully clawed back. While Purdue filed bankruptcy (2019) and agreed to settlement terms, the Sackler family has pursued complex structures to shield billionth-of-dollar assets. Their name has been removed from museums and institutions, but the fortunes remain largely intact, a reflection of how wealthy families navigate accountability in ways ordinary individuals cannot.

FAQ

Did Purdue Pharma know OxyContin was addictive?

Yes. Internal company documents from the 1990s, submitted as evidence in multiple court cases, show executives received research indicating high addiction potential. Richard Sackler's emails and deposition testimony confirm he was aware of addiction concerns by 1997. The company continued marketing OxyContin as having "minimal addiction risk" despite this internal knowledge. This is documented in the 2007 federal guilty plea and 2020 settlement admissions.

What did the FDA do?

The FDA approved OxyContin in 1995 based on limited addiction safety data. When Purdue submitted misleading marketing materials claiming low addiction risk, the FDA initially objected, but the company resubmitted and the FDA approved the claims. Internal FDA memos later disclosed through FOIA show FDA scientists were skeptical of Purdue's addiction data. In 2003, under Purdue pressure, the FDA removed prominent addiction warnings from the label. The agency's role in approving misleading marketing is a central failure documented in the FDA's own records.

How much money did Purdue make from OxyContin?

OxyContin generated over $35 billion in revenue for Purdue Pharma between 1996 and 2018. Peak annual sales exceeded $3 billion. Settlement and bankruptcy documents filed in federal court show the company paid approximately $600 million in dividends to the Sackler family between 1996 and 2015, even as opioid deaths mounted.

What happened to Purdue executives?

In the 2007 criminal case, three executives (Friedman, Udell, and Scranton) pleaded guilty to misdemeanor charges and received no prison time, though they paid fines. Richard Sackler was not criminally charged despite evidence of direct involvement in marketing decisions. The 2020 bankruptcy settlement included admissions of wrongdoing but limited individual accountability. This disparity is documented in DOJ court filings and widely criticized by prosecutors and public health experts.

Is the Sackler family's wealth affected by settlements?

Settlements extracted billions from Purdue Pharma, but the Sackler family's personal wealth, estimated at $11 billion, remains substantially intact. The family has used complex legal structures and asset protection strategies to shield personal assets from liability. Documents filed in bankruptcy and litigation reveal the family's sophisticated financial architecture, which is discussed extensively in investigative reporting and court filings but remains largely legal under current law.

---

Related Documentation:

For comprehensive case records, see the Department of Justice press release on the 2007 Purdue settlement and the 2020 Purdue bankruptcy filing with attached Complaint and Settlement Agreement. The DEA's National Drug Threat Assessment reports (1998-2005) document the rise in opioid diversion. Additional discovery documents are archived through journalist investigative projects that have digitized court filings.

For discussion of broader pharmaceutical fraud patterns, see related claims. The Purdue case intersects with documented failures in FDA oversight mechanisms and government regulatory agencies.